Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cytokinetics, Inc. (CYTK) Conference Call Transcript – Expansion of Collaboration Agreement with Astellas

Page 1 of 9

Below is the Cytokinetics, Inc. (NASDAQ:CYTK) conference call transcript regarding the expansion of collaboration agreement with Astellas held on Monday, January 5, 2015 at 8:30 a.m.

Cytokinetics, Inc. (NASDAQ:CYTK)

Participants:

Sharon Barbari, Cytokinetics Executive Vice President of Finance and Chief Financial Officers

Robert Blum, President and Chief Executive Officer

Fady I. Malik, SVP, Research and Development

 

Operator

Good morning and welcome ladies and gentlemen to this Cytokinetics conference call. At this time I would like to inform you that this call is being recorded and that all participants are in a listen only mode. At the request of the company we will open up the call for Q&A after the presentation. I will now turn the call over to Sharon Barbari, Cytokinetics Executive Vice President of Finance and Chief Financial Officers. Please go ahead.

Sharon Barbari, Cytokinetics Executive Vice President of Finance and Chief Financial Officers

Good morning and thank you for joining this side of Cytokinetics Senior Management Team on this conference call today. Also present during this call are Robert Blum our President and Chief Executive Officer and Dr. Fady Malik PhD Senior Vice President of Research and Development. The following discussion including our responses to questions contain statement that constitute forward looking statements for the purposes of the Safe Harbor Provisions of the private securities litigation format of 1995 including but not limited to statements relating to our financial guidance and corporate partnering to the initiation, enrolment, design, conduct and results of clinical trials and to other research and development activities.

Our actual results might differ materially from those projected in these forward looking statements. Additional information concerning factors that could cause our actual results to differ materially from these forward looking statements is contained in our SEC filings, including our most recent annual report on form 10 K, our quarterly reports on form 10 Q and our current report on form 8 K. Copies of these documents may be obtained from the SEC or by visiting the Investor Relation section of our website. These forward looking statements speak only as if today. You should not rely on them as representing our views in the future. We undertake no obligations to update these statements after this call. Now I will turn the call over to Robert Blum.

Page 1 of 9
Loading...